Insmed Inc (INSM)vsSinovac Biotech Ltd (SVA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SVA
Sinovac Biotech Ltd
$6.47
0.00%
HEALTHCARE · Cap: $642.44M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 19% more annual revenue ($606.42M vs $510.62M). SVA leads profitability with a 21.6% profit margin vs -2.1%. SVA earns a higher WallStSmart Score of 78/100 (B+).
INSM
Hold39
out of 100
Grade: F
SVA
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for INSM.
Margin of Safety
+85.8%
Fair Value
$45.44
Current Price
$6.47
$38.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 42.3%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
3.0% revenue growth
3.5% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SVA
The strongest argument for SVA centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 42.3%.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SVA
The primary concerns for SVA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while SVA is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
SVA is growing revenue faster at 3.0% — sustainability is the question.
SVA generates stronger free cash flow (93M), providing more financial flexibility.
Bottom Line
SVA scores higher overall (78/100 vs 39/100), backed by strong 21.6% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Sinovac Biotech Ltd
HEALTHCARE · BIOTECHNOLOGY · China
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture and marketing of vaccines against human infectious diseases in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?